Other
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Moderna Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss increased by 218.9% to $3.87B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.9%, from $3.13B to $3.87B. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss shows a downward trend with a -40.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2019
Last reportedQ1 2026May 1, 2026
Metric ID:
other_debt_securities_available_for_sale_unrealized_loss_2eb75fHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.35B | $13B | $14.16B | $13.52B | $13.16B | $11.12B | $10.55B | $9.16B | $8.01B | $8.77B | $8.26B | $4.47B | $4.32B | $3.13B | $2.56B | $1.37B | $1.21B | $3.87B |
| QoQ Change | — | +39.1% | +8.9% | -4.5% | -2.7% | -15.5% | -5.1% | -13.2% | -12.5% | +9.4% | -5.8% | -45.9% | -3.3% | -27.6% | -18.0% | -46.6% | -11.3% | +218.9% |
| YoY Change | — | — | — | — | +40.8% | -14.5% | -25.5% | -32.2% | -39.1% | -21.1% | -21.7% | -51.3% | -46.1% | -64.4% | -69.0% | -69.4% | -71.9% | +23.9% |
Range$1.21B – $14.16B
CAGR-18.7%
Avg YoY Growth-33.0%
Median YoY Growth-35.7%
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss at Other Companies
Frequently Asked Questions
- What is Moderna's debt securities, available-for-sale, unrealized loss position, accumulated loss?
- Moderna (MRNA) reported debt securities, available-for-sale, unrealized loss position, accumulated loss of $3.87B in Q1 2026.
- How has Moderna's debt securities, available-for-sale, unrealized loss position, accumulated loss changed year-over-year?
- Moderna's debt securities, available-for-sale, unrealized loss position, accumulated loss increased by 23.9% year-over-year, from $3.13B to $3.87B.
- What is the long-term trend for Moderna's debt securities, available-for-sale, unrealized loss position, accumulated loss?
- Over 4 years (2021 to 2025), Moderna's debt securities, available-for-sale, unrealized loss position, accumulated loss has grown at a -40.0% compound annual growth rate (CAGR), from $9.35B to $1.21B.